Too Bad to Be True: What Can We Reasonably Expect for Treatments of Multiple Organ Failure?
- PMID: 35984066
- DOI: 10.1097/CCM.0000000000005578
Too Bad to Be True: What Can We Reasonably Expect for Treatments of Multiple Organ Failure?
Conflict of interest statement
Dr. Pappalardo declares to have received speaker fee regarding Cytosorbents. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Comment in
-
The authors reply.Crit Care Med. 2022 Sep 1;50(9):e729-e730. doi: 10.1097/CCM.0000000000005597. Epub 2022 Aug 15. Crit Care Med. 2022. PMID: 35984067 No abstract available.
Comment on
-
CytoSorb Rescue for COVID-19 Patients With Vasoplegic Shock and Multiple Organ Failure: A Prospective, Open-Label, Randomized Controlled Pilot Study.Crit Care Med. 2022 Jun 1;50(6):964-976. doi: 10.1097/CCM.0000000000005493. Epub 2022 Feb 9. Crit Care Med. 2022. PMID: 35135967 Free PMC article. Clinical Trial.
References
-
- Stockmann H, Thelen P, Stroben F, et al.: CytoSorb rescue for COVID-19 patients with vasoplegic shock and multiple organ failure: A prospective, open-label, randomized controlled pilot study. Crit Care Med 2022; 50:964–976
-
- Sanfilippo F, Martucci G, La Via L, et al.: Hemoperfusion and blood purification strategies in patients with COVID-19: A systematic review. Artif Organs 2021; 45:1466–1476
-
- Extracorporeal Life Spuport Organization: Registry Dashboard of ECMO-Supported COVID-19 Patient Data. Available at: https://www.elso.org/Registry/FullCOVID19RegistryDashboard.aspx . Accessed May 15, 2021
-
- Zanella A, Florio G, Antonelli M, et al.; COVID-19 Italian ICU Network: Time course of risk factors associated with mortality of 1260 critically ill patients with COVID-19 admitted to 24 Italian intensive care units. Intensive Care Med 2021; 47:995–1008
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
